-
Disease management is a fluid process that often involves transitioning patients from the disease management team to case management for more intensive interventions, says Pam Mays, MPH, BSRN, RN, assistant vice president for care management of CIGNA Health Care.
-
As a case manager, you are well accustomed to working in a number of roles. However, those roles can become complex when your patient advocate role does not mesh with the obligations you have to your employer.
-
For people with asthma, the viral infections that cause the common cold are a major cause of health emergencies, including hospitalizations, a study at the University of Iowa Health Care has concluded.
-
-
Elevated CRP levels are associated with inducible ischemia in patients with stable coronary disease, particularly among those not treated with beta-blockers or statins.
-
Syncope, Driving Recommendations, and Clinical Reality: Survey of Patients; Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE): A Randomized Controlled Trial; Early Onset of Action and Efficacy of a Combination of Calcipotriene and Betamethasone Dipropionate in the Treatment of Psoriasis
-
Clinical Scenario: The ECG in the Figure shows normal sinus rhythm at a rate of 80 beats/minute. The PR, QRS, and QT intervals are normal. There is an rSR pattern in lead III. The axis is +40°. There is no sign of chamber enlargement. The most remarkable finding on this tracing is the presence of subtle but real ST segment elevation in multiple leads including I, II, aVF, and V2 through V6.
-
Smallpox Vaccination Guidelines Published by CDC; Nurses: Delay
Vaccination Program; Viagra Effective for Depression Treatment;
Finisteride/Doxazosin no Better than Placebo for Urinary Obstruction;
Serevent Receives Dear Doctor Letter
-
Women who habitually sleep 5 or fewer or 9 or more hours per night have an increased risk of coronary heart disease compared with those who sleep 7 or 8 hours a night.
-
Alefacept is a new biological agent for the treatment of moderate-to-severe plaque psoriasis. The drug, which targets T lymphocytes, is a fusion protein combining the binding site of lymphocyte function-associated antigen-3 and the Fc portion of human IgG1.
